Cronos Group Inc (CRON)vsMerck & Company Inc (MRK)
CRON
Cronos Group Inc
$3.14
-0.63%
HEALTHCARE · Cap: $1.16B
MRK
Merck & Company Inc
$143.93
-0.54%
HEALTHCARE · Cap: $355.10B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 37071% more annual revenue ($66.57B vs $179.09M). CRON leads profitability with a 39.1% profit margin vs 4.8%. CRON trades at a lower P/E of 16.5x. CRON earns a higher WallStSmart Score of 61/100 (C+).
CRON
Buy61
out of 100
Grade: C+
MRK
Hold36
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for CRON.
Margin of Safety
-73.7%
Fair Value
$82.84
Current Price
$143.93
$61.09 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Keeps 39 of every $100 in revenue as profit
Revenue surging 58.4% year-over-year
Earnings expanding 126.8% YoY
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Mega-cap, among the largest globally
Generating 4.5B in free cash flow
Areas to Watch
Smaller company, higher risk/reward
ROE of -0.2% — below average capital efficiency
Trading at 8.5x book value
ROE of 7.6% — below average capital efficiency
4.8% margin — thin
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : CRON
The strongest argument for CRON centers on Price/Book, Profit Margin, Revenue Growth. Profitability is solid with margins at 39.1% and operating margin at 15.4%. Revenue growth of 58.4% demonstrates continued momentum.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Free Cash Flow.
Bear Case : CRON
The primary concerns for CRON are Market Cap, Return on Equity.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 116.1x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.
Key Dynamics to Monitor
CRON profiles as a growth stock while MRK is a value play — different risk/reward profiles.
CRON carries more volatility with a beta of 1.28 — expect wider price swings.
CRON is growing revenue faster at 58.4% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Bottom Line
CRON scores higher overall (61/100 vs 36/100), backed by strong 39.1% margins and 58.4% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Cronos Group Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Cronos Group Inc. is a cannabinoid company. The company is headquartered in Toronto, Canada.
Visit Website →Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?